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Prevalence, pathogenesis, and functional significance of aldoste-
rone deficiency in hyperkalemic patients with chronic renal in-
sufficiency. Plasma and urinary aldosterone levels and plasma re-
nm activity (PRA) were measured to determine the prevalence,
pathogenesis, and functional significance of aldosterone defi-
ciency in hyperkalemic patients with chronic renal insufficiency
(creatinine clearance, 31 2 mI/mm). In 31 such patients, uri-
nary aldosterone (UAdOV) ranged from 0.8 to 10.9 gI24 hours
(normal subjects, 4.2 to 16.6 jig/24 hours; N = 29). Because po-
tassium ordinarily stimulates aldosterone secretion, UAIdOV was
expressed as a function of serum potassium (UAIdOV/SK). In 23
patients, UAJdOV/SK was subnormal (subgroup A); in 8 patients,
UAIdOV/SK was within the normal range (subgroup B). In both
groups, UAIdOV and SK correlated positively, but UAIdOV was
lower in subgroup A at any SK. Serum potassium correlated with
urinary potassium excretion (UKV) in both subgroups, but for
any UKV, SK was greater in subgroup A. In all but one patient in
subgroup B, PRA was within normal limits. In subgroup A, 19
patients had subnormal PRA. In these patients (hyporeninemic
hypoaldosteronism), stimulation of PRA by sodium chloride de-
pletion was blunted, yet plasma aldosterone concentration (PAIdO)
and PRA correlated positively (PAIdO, 10.8 PRA + 5.1; r = 0.97;
P < 0.01), with a slope not significantly different from that in
normal subjects (PAIdO, 14.5• PRA — 9.4;r = 0.98,P <0.01). The
remaining 4 patients in subgroup A had normal PRA values. De-
spite significantly greater values of SK in these 4 patients with
normoreninemic hypoaldosteronism, PAId,, was significantly
lower than it was in subgroup B patients and normal subjects at
similar values of PRA. When PRA was stimulated further by so-
dium depletion in 2 of the 4 patients so studied, the increase in
PAId,, was blunted. The findings indicate that hypoaldosteronism
occurs commonly (23/31 patients) in hyperkalemic patients with
chronic renal insufficiency and that the deficiency of aldosterone
contributes to the pathogenesis of the hyperkalemia. In most pa-
tients (83%), hypoaldosteronism could be accounted for by
deficient renal secretion of renin, but in some patients (17%),
renin deficiency did not appear to be present, and therefore other
(unidentified) causes of aldosterone deficiency must be invoked.
La fréquence, Ia pathogénie, et Ia signification fonctionnelle du
deficit d'aldostérone chez les malades hyperkaliémiques au cours
de l'insuffisance rénale chronique. Les concentrations plasma-
tiques et urinaires d'aldostérone et l'activité rénine plasmatique
(PRA) ont été mesurées pour determiner Ia fréquence, Ia path-
ogénie et Ia signification fonctionelle du deficit d'aldostérone
chez les malades hyperkaliemiques au cours de l'insufllsance ré-
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nale chronique (clearance de Ia créatinine, 31 2 mllmin). Chez
31 de ces malades l'aldostéronurie (UAIdOV) variait de 0,8 a 10,9
g/24 heures (sujets normaux, 4,2 a 16,6 g/24 heures; N = 29).
Puisque Ic potassium stimule habituellement Ia sécrétion
d'aldostérone, UAIdOV a été exprimé en fonction de Ia kaliémie
(UAIdOV/SK). Chez 23 malades, UAIdOV/SK était subnormal (sous
groupe A); chez 8 malades, UAIdOV/SK était dans l'intervalle des
valeurs normales (sous groupe B). Dans les deux cas UAIdOV et
SK Ctaient positivement corrélés, mais UAIdOV était inférieur
dans le sous groupe A pour toutes les valeurs de SK. LakaliCmie
était corrélée avec l'excrétion de potassium urinaire (UKV) dans
les deux sous groupes, mais pour un UKV donné, S Ctait plus
grand dans Ic sous groupe A. Chez tous les malades du sous
groupe B sauf un, PRA était dans les limites normales. Dans Ic
sous groupe A, 19 malades avaient une PRA inferieure a Ia nor-
male. Chez ces malades (hypoaldostéronisme hyporéninémique)
Ia stimulation de PRA par Ia déplétion en chiorure de sodium
était faible, bien que l'aldostéronémie (PAIdO) et PRA étaient pos-
itivement corrélées (PAIdO, 10,8 PRA + 5,1;r = 0,97;P <0,01)
avec une pente non significativement diffCrente de celle des su-
jets normaux (PAIdO, 14,5 PRA — 9,4; r = 0,98; P < 0,01). Les
quatre autres malades du sous groupe A avaient des valeurs nor-
males de PRA. Malgré des valeurs significativement supérieures
de SK chez ces quatre malades atteints d'hypoaldostéronisme hy-
poréninémique, PAIdO Ctait significativement inférieur chez les
malades du sous groupe B et les sujets normaux pour des valeurs
semblables de PRA. La stimulation de PRA par Ia déplétion en
sodium chez deux de ces quatre malades n'a donné qu'une aug-
mentation minime de PAIdO. Ces constatations indiquent que
l'hypoaldostéronisme est frequent (23/31 malades) chez Ies mal-
ades hyperkaliCmiques au cours de l'insuffisance rénale chro-
nique et que le deficit d'aldostérone contribue a I'hypokaliémie.
Chez Ia plupart des malades (83%) l'hypoaldosteronisme peut
étre expliqué par un deficit de Ia sCcrétion rénale de rCnine, mais
chez quelques malades (17%) le deficit de rénine n'est pas con-
state et par consequent d'autres causes de deficit d'aldostérone
doivent être invoquées.
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Secretion of aldosterone by the adrenal gland pro-
vides critical regulation of body potassium ion
homeostasis. In disorders of the adrenal gland char-
acterized by subnormal secretion of aldosterone,
renal clearance of potassium is diminished, and po-
tentially severe hyperkalemia may result. Aldoste-
rone deficiency can occur in several adrenal dis-
orders in association with deficient secretion of oth-
er major adrenocortical hormones (for example,
Addison's disease, 21 -hydroxylase deficiency), or
without generalized adrenocortical insufficiency
(isolated hypoaldosteronism) as a consequence of
inherited enzyme defects in the biosynthetic path-
ways specific for aldosterone (corticosterone
methyl oxidase deficiency) [1-4]. In recent years,
isolated hypoaldosteronism has been recognized
with increasing frequency in adults [5—14] as a pre-
sumed acquired disturbance secondary to deficient
renal secretion of renin [15—23]. In a small number
of such adult patients, an abnormality in activation
of renin [22] and/or a defect in aldosterone biosyn-
thesis may also be present [11, 15, 22].
Isolated hypoaldosteronism in adults occurs most
commonly in association with chronic diseases of
the kidney that reduce the glomerular filtration rate.
The diagnosis is suspected in patients who have
chronic hyperkalemia unassociated with oliguria or
far-advanced renal insufficiency and is confirmed
usually by measurement of the urinary excretion
rate of aldosterone-l8-glucuronide, a metabolite of
aldosterone produced predominantly in the kidney
[24]. Whether or not the urinary excretion rate of
aldosterone-l8-glucuronide provides a valid index
of aldosterone secretion rate in patients with chron-
ic renal diseases as it does in normal persons has
not been investigated. Furthermore, a diagnosis of
"hypoaldosteronism" cannot be based solely on an
estimate of aldosterone secretion rate or even on
measurement of plasma aldosterone concentration,
because assessment of the physiologic appropriate-
ness of aldosterone secretion or concentration re-
quires simultaneous consideration of the stimula-
tory influence of the renin-angiotensin system and
plasma potassium concentration on aldosterone
biosynthesis. Hyperkalemia, for example, ordinari-
ly stimulates aldosterone secretion [25, 26] so that
normal" aldosterone levels may be abnormally
low in hyperkalemic patients. Owing to the relative-
ly small numbers of patients reported in published
studies, the diagnostic criteria and prevalence of
hypoaldosteronism in hyperkalemic patients with
chronic renal insufficiency have not been estab-
lished nor have the frequency and extent to which
renin deficiency can be implicated in its pathogene-
sis been determined.
We therefore examined plasma and urinary al-
dosterone levels, aldosterone secretion rate, and
plasma renin activity (PRA) in a large group of hy-
perkalemic patients with chronic renal insufficien-
cy. The results indicate that hypoaldosteronism is a
prevalent and functionally significant abnormality
in such patients and that it is most commonly but
not invariably caused by hyporeninemia.
Methods
Study population. Thirty-one adult patients with
hyperkalemia and chronic renal insufficiency, rang-
ing from 32 to 81 years of age, were admitted to the
Clinical Study Center, San Francisco General Hos-
pital Medical Center, or the General Clinical Re-
search Center, University of California, San Fran-
cisco. Serum potassium concentrations ranged from
6.0 to 8.7 mEq/liter when dietary potassium was ad
lib and creatinine clearance ranged from 10 to 56 ml!
min!l.73 m2. Seven patients had diabetes mellitus,
one had multiple myeloma, and the majority of the
remainder had clinical characteristics consistent
with interstitial nephritis [27]. Addison's disease
was excluded by the demonstration of normal levels
of plasma cortisol and/or urinary excretion of 17-
hydroxycorticosteroids. In addition, 29 normal sub-
jects, ranging in age from 21 to 62 years, were stud-
ied for purposes of comparison.
Study conditions. All studies were carried out un-
der conditions in which the patients and normal
subjects ingested a constant diet containing 6 to 26
mEq of sodium per day supplemented by 6 g of so-
dium chloride per day in capsular form. Because of
the risks attending hyperkalemia, dietary potassium
was restricted (47 3 vs. 68 4 LsEM] mEq!day in
normal subjects; P < 0.001) to minimize the degree
of hyperkalemia during the course of the studies.
This maneuver resulted in normalization of serum
potassium concentration during the control period
in 5 patients; 3 of these patients had documented
episodes of hyperkalemic cardiotoxicity prior to the
study. Two patients also received sodium bicarbon-
ate, 84 and 100 mEq!day, respectively, for treat-
ment of metabolic acidosis.
Protocols: (1) Control measurements. The 24-
hour urinary excretion rate of aldosterone-18-glu-
curonide was measured in all patients and control
subjects. The measurements were obtained on day
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3 of a 3-day period in which urinary excretion of
sodium and potassium were stable. On the same
day, blood specimens were obtained for the mea-
surement of PRA, plasma aldosterone concentra-
tion, and sodium and potassium concentrations at
8:00 A.M. after overnight recumbency and after 4
hours of upright activity. In 3_patients and 4 normal
subjects, blood specimens were also obtained every
4 hours in a single 24-hour period (circadian study).
In 7 patients and 4 normal subjects, aldosterone se-
cretory rate was determined by measuring the spe-
cific activity of the 18-glucuronide metabolite of a!-
dosterone in urine samples collected for 48 hours
after a single injection of 4 to 8 tCi of 1 ,2-3H-al-
dosterone.
(2) Stimulation of the renin-angiotensin system.
The effect of stimulation of the renin-angiotensin
system on aldosterone production was evaluated in
15 patients and 6 normal subjects by inducing so-
dium depletion. In 14 patients and the normal sub-
jects, sodium depletion was effected by discontin-
uing the sodium chloride supplements for a period
of 3 to 5 days. This resulted in an average negative
sodium balance of 182 17 and 56 13 mEq and an
average weight loss of 1.3 0.2 and 0.8 0.3 kg in
the patients and normal group, respectively. Uri-
nary excretion of aldosterone was determined on
days 3 and 5 of sodium restriction, and recumbent
and upright blood samples were obtained the fol-
lowing mornings. In one patient, sodium depletion
was effected by administration of furosemide, 40 to
80 mg/day orally, for 13 days, which resulted in a
negative sodium balance of 364 mEq and a weight
loss of 2.6 kg. Blood and urine samples were ob-
tained after days 9 and 13 of drug administration.
(3) increased serum potassium. The effect of an
increase in serum potassium concentration on al-
dosterone production was evaluated in three pa-
tients by increasing potassium intake by 24 to 48
mEq/day for a period of 5 to 7 days. Urinary al-
dosterone excretion and plasma aldosterone con-
centration were determined before and at the com-
pletion of potassium loading.
Experimental protocols were reviewed and ap-
proved by the Committee on Human Research,
University of California, San Francisco, and in-
formed consent was obtained from all subjects.
Analytical methods. Urinary sodium and potas-
sium concentrations were measured by a flame pho-
tometer, and serum electrolytes and creatinine by
an autoanalyzer. Plasma renin activity was deter-
mined by radioimmunoassay of generated angioten-
sin I as described previously [28, 29]' and plasma
aldosterone concentration by radioimmunoassay
[30].
The excretion rate of aldosterone-18-glucuromde
was determined by double isotope dilution assay
[31]. The secretory rate of aldosterone was e6ti-
mated by measurement of the specific activity of the
18-glucuronide metabolite [32] in the urine collected
in the first 24 hours after administration of the iso-
tope. Because of the delay in isotope excretion that
occurs in patients with impaired renal function, cal-
culation of the secretion rate based on the specific
activity of the metabolite in the first 24-hour urine
specimen results in an overestimation of the true a!-
dosterone secretory rate. Accordingly, the true se-
cretory rate was estimated by multiplying the ob-
served secretory rate by a correction factor that
was derived from analysis of isotope excretion in 2
consecutive 24-hour urine specimens, as suggested
by Cope and Pearson [33]. In their formulation, the
correction factor is I — (B/U), where U and B are
the observed percentages of the administered iso-
tope that appear in the first and second 24-hour
urine specimens, respectively.
Statistical significance was determined by Stu-
dent's t test for paired or unpaired variables, linear
regression analysis, and analysis of covariance [34].
Results
Assessment of aldosterone production. In the 31
patients with chronic renal insufficiency, urinary
excretion of aldosterone-18-glucuronide ranged
from 0.8 to 10.9 tg/24 hours (Table 1). Because a!-
dosterone secretion is normally modulated by small
changes in serum potassium concentration, we ana-
lyzed these excretion rates in each patient in rela-
tion to the corresponding serum potassium concen-
tration (Fig. 1). The ratio of urinary aldosterone ex-
cretion rate to serum potassium concentration
(UAIdOV/SK) in each patient was compared with
those in the normal subjects studied (Fig. 1). Two
subgroups of patients were thereby delineated: sub-
group A comprised 23 patients (nos. I to 23) in
'In the methods described [28, 29], angiotensin I concentration
was determined using a standard provided by Dr. F. Merlin
Bumpus. In the present assay, the standards were obtained from
Beckman Instruments, Inc. The standard curves for the two as-
says are parallel, and the interassay difference is constant. Val-
ues for PRA in previous publications [16, 20, 23], reported in
nanograms per milliliter per 3 hours, can be compared with val-
ues in the current study, reported in nanograms per milliliter per
hour, by multiplying by 0.23.
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whom UAI(IOV/SK was less than in all of the normal
subjects; and subgroup B comprised 8 patients (nos.
24 to 31) in whom UAIdOV/SK was within the range of
values for the normal subjects. There was also no
overlap in the absolute excretion rates of aldoste-
rone in the 2 subgroups (nos. I to 23 vs. nos. 24 to
31, Table 1).
It is noteworthy that within each subgroup the
urinary aldosterone excretion rate correlated posi-
tively with the serum potassium concentration (Fig.
2). At every level of serum potassium concentra-
tion, however, urinary aldosterone excretion ap-
peared to be lower in subgroup A than it was in sub-
group B. Mean urinary aldosterone excretion in
subgroup A was significantly less than that in the
normal group (Table 2). The patients in subgroup A
were diagnosed as having "isolated hypoaldoste-
ronism."
In subgroup A there was a significant negative
correlation between UAJdOV/SK and the age of the
patients (UAIdOV/SK, —1.4 . age (yr) + 1.5; r =
—0.56; P <0.01), but no such correlation was noted
in subgroup B or the normal subjects. The ages of
15 of the 23 patients in subgroup A fell within the
range of ages in the normal subjects. The ages of
these 15 patients ranged from 32 to 65 years. Selec-
tion of those normal subjects who fell in this age
range (N = 23), therefore, provides an age-adjusted
control population for the majority of patients in
subgroup A. Within this age range, there was no
overlap between values of the ratio UAIdOV/SK in pa-
tients in subgroup A with those of the normal sub-
jects and patients in subgroup B whose ages were
similar (Fig. 1).
Studies were carried out to investigate whether or
not the urinary excretion rate of aldosterone-18-glu-
Table 1. Clinical and biochemical characteristics in patients with chronic renal insufficiencya
Urinary
Pa-
tient
no.
Age
(yr)/
sex
Creatinine
clearance
ml/min/I.73 m2
Urinary
aldosterone
u.g/24 hr
Plasma aldosterone
ng/dl
PRA
ng/n!/hr
Serum electrolytes
mEq/Iiter
electrolytes
mEq/24 hr
Recumbent Upright Recumbent Upright Na K Cl HC03 Na K
I 64/F 32 0.8 3.7 4.2 0,7 2.4 135 4.4 103 23 79 14
2 68/F 42 0.8 2.7 2.2 <0.1 <0.1 138 4.6 108 26 176 21
3 70/M 10 1.3 <1.0 2.6 1.6 2.1 134 4.4 100 23 47 II
4 76/M 35 1.3 3.4 4.8 0.1 0.2 142 4.8 115 23 28 15
5 74/M 16 1.5 7.7 4.5 0.1 0.1 137 5.8 112 16 64 22
6 59/F 53 1.6 5.6 6.2 0.2 0.7 134 5.4 115 17 79 36
7 81/M 40 1.9 7.6 5.7 0.4 0.5 137 5.2 109 22 120 37
8 66/M 39 2,0 3.0 4.0 0.1 0.3 139 5.3 107 19 97 45
9 73/M 33 2.4 2.7 3.6 0.3 0.7 138 5.3 110 20 147 22
10 48/M 22 2.4 2.2 2.1 <0.1 <0.1 138 5.3 116 16 94 12
11 76/M 13 2.6 8.0 10.2 <0.1 0.3 138 5.7 116 17 114 24
12 57/F 44 2.9 5.6 3.1 0.7 1.3 139 5.2 III 20 88 26
13 52/F 41 3.1 6.4 9.3 0.3 0.4 140 5.2 107 24 223 36
14 63/F 56 4.0 5.0 12.2 0.3 0.5 141 5.0 112 22 57 22
15 32/F 44 4.4 6.8 18.2 0.6 1.8 142 5.0 111 19 91 35
16 61/F 15 4.4 6.4 17.0 0.4 0.5 138 5.5 106 15 93 43
17 65/M 18 4.5 5.0 12.9 <0.1 <0.1 140 5.9 118 15 115 22
18 50/F 12 4.5 3.4 35.4 0.1 0.2 144 5.4 122 17 120 29
19 61/M 21 5.0 10.2 4.6 0.2 0.3 139 5.1 113 21 166 24
20 54/F 55 5.1 10.8 9.7 0.6 0.7 129 5.8 94 25 63 24
21 64/M 13 5.7 14.7 6.6 0.2 0.4 140 5.6 116 IS 128 36
22 4l/M 50 6.1 5.8 9.5 0.4 0.6 131 5.7 101 23 83 60
23 61/M 34 6.2 5.9 4.5 0.2 0.2 141 6.3 116 21 100 60
24 59/M 27 6.8 7.5 12.3 0.4 0.8 142 4.5 111 17 104 20
25 67/M 33 7.0 — — 1.2 4.1 142 5.0 111 19 98 29
26 57/M 24 7.3 15.4 12.0 0.8 2.1 134 4.9 101 20 60 41
27 49/M 41 8.7 24.2 27.0 0.7 1.1 135 4.9 106 22 109 54
28 62/M 15 8.9 28.9 49.9 1.2 1.2 138 5.1 116 18 124 54
29 52/F 22 9.1 24.7 70.0 0.8 1.7 140 4.9 114 11 77 37
30 56/M 22 10.2 11.5 32.7 0.6 2.0 138 5.0 107 21 III 54
31 68/M 42 10.9 — — 0.6 2.7 139 5.4 110 23 129 69
Mean 61 31 4.6 7.9 12.8 0.4 1.0 138 5.2 110 20 103 33
SEM 2 2 0.5 1.3 2.8 0.1 0.2 I 0.1 1 1 7 3
a Patients are listed in order of increasing urinary aldosterone excretion. Patients nos. 1, 2, 8, 13, 14, 16, and 22 had diabetes mellitus,
and patient no. 6 had multiple myeloma. Values for the excretion rates of sodium and potassium are the mean of three consecutive 24-hr
urine samples collected while the patients were ingesting a diet of low-sodium content (6 to 26 mEq/day) supplemented by sodium
chloride capsules (6 g/day). Patients nos. 2 and 13 also received sodium bicarbonate (84 and 100 mEq/day, respectively).
Fig. 1. Values for the ratio of urinary excretion of aldosterone—
/8—glucuronide to serum potassium concentration (UAI,,V/SK) in
patients with hyperkalemia and chronic renal insufficiency (solid
symbols and asterisks) and in normal subjects (open circles).
Two subgroups of patients are identified: 23 patients (solid sym-
bols) in whom values of this ratio are below the range in normal
subjects (shaded area) and 8 patients (asterisks) in whom the
value of this ratio fell within the normal range. On this and sub-
sequent figures the separatesolidsy,nhols (triangle, diamond, in-
verted triangle, and square) depict patients I, 3, 12, and 15, re-
spectively.
curonide is a valid index of aldosterone secretion
rate and plasma aidosterone concentration in pa-
tients with chronic renal insufficiency. In 7 patients
in whom the aldosterone secretion rate was mea-
sured, the mean ratio of the excretion rate of al-
dosterone-18-glucuronide to the corresponding cor-
rected secretion rate (ER/SRcorr) was 0. 10 0.01;
this value was not significantly different from that in
the normal subjects studied, 0.09 0.01 (Table 3).
A highly significant linear correlation was observed
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Fig. 2. Relationship hetia'een urinary aldosterone excretion and
serum potassium concentration in patients with isolated hypoal—
dosteronism (subgroup A) (solid symbols) and patients with
chronic renal insufficiency without hypoaldosteronism (subgroup
B) (asterisks). The patients with hyporeninemic hypoaldosteron-
ism are depicted by the solid circles and those with normoreni-
nemic hypoaldosteronism by the other solid symbols. As in-
dicated by the regression lines, a significant positive correlation
between urinary aldosterone excretion and serum potassium
concentration was observed in both the patients with hypoal-
dosteronism (y = 2.32x — 9.1; r = 0.63; P < 0.01) and in those
without hypoaldosteronism (y = 4.38x — l3.l r = 0.73; P <
0.05). The slopes did not differ significantly in the two groups
(analysis of covariance). The shaded areas indicate the 95% con-
fidence limits for each regression analysis.
between the values of the excretion of aldosterone-
18-glucuronide and the corresponding corrected se-
cretion rates both in the patients and normal sub-
jects (Fig. 3A). In 3 patients and 4 normal subjects,
a highly significant positive linear correlation was
also observed between the urinary excretion rate of
aldosterone- I 8-glucuronide and the mean plasma a!-
dosterone concentration determined at 4-hourly in-
tervals throughout the same 24-hour period (Fig.
3B).
In the patients with isolated hypoaldosteronism
(subgroup A), mean plasma aldosterone concentra-
tion was significantly less than the mean in the nor-
mal subjects and patients with chronic renal in-
sufficiency without hypoaldosteronism (subgroup
B) (Table 2, recumbent and upright values). With
the assumption of upright posture, no significant
change in plasma aldosterone concentration oc-
curred in the patients with hypoaldosteronism,
C,)
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Table 2. Comparison of clinical and biochemical characteristics in the two subgroups of patients with chronic renal insufficiency and in
control subjects
Urinary
Age
yr
Ccrt
mi/mini
I.73m2
UAIdOV
agi24 hr
PAIdO PRA
ngidi ngi,niihr
Serum electrolytes
mEqiliter
electrolytes
,nEq/24 hr
Recumbent Upright Recumbent Upright Na K C1 HC03 Na K
62 32 3.2
Subgroup A (N = 23)
5.8 8.4 0.3 0.6 138 5.3 110 19 103 29
±2 ±3 ±0.4 ±0.7 ±1.6 ±0.1 ±0.1
Subgroup B (N = 8)
±1 ±0.1 ±1 ±1 ±9 ±3
59 28 8.6 18.7 34.0 0.8 2.0 138 5.0 110 19 102 45
±2 ±3 ±0.5 ±3.5 ±9.2 ±0.1 ±0.4
Normal control subjects (N = 29)
±1 ±0.1 ±2 ±1 ±8 ±6
43 102 10.7 9.6 20.9 1.0 2.4 141 4.3 107 25 108 55
±2 ±5 ±0.8 ±1.0 ±2.1 ±0.1 ±0.5
Intergroup comparisons: P values
±1 ±0.1 ±1 ±1 ±4 ±3
Avs.B NS NS <0.001 <0.001 <0.001 <0.005 <0.001 NS NS NS NS NS <0.02
A vs. NCS <0.001 <0.001 <0.001 <0.005 <0.001 <0.001 <0.001 <0.001 <0.001 <0.05 <0.001 NS <0.001
B vs. NCS <0.001 <0.005 NS <0.005 NS NS NS <0.001 <0.001 NS <0.001 NS NS
Values are mean ± SEM. NS is not significant; NCS, normal control subjects.
"Intergroup comparisons were carried out by Student's t test for unpaired variables.
Table 3. Determination of aldosterone production in patients
with chronic renal insufficiency
Aldosterone
production5
Patient
no.
Cçret
2 Correction
p.g/24 hr
,nl/min/l.73 'n factor SReorr ER ER
S Reorr
15
Chronic renal insufficiency
44 0.82 62 4.4 0.07
I 32 0.73 12 0.8 0.07
10 22 0.57 14 2.2 0.16
29 22 0.61 124 7.1 0.06
30 22 0.57 118 11.8 0.10
19 21 0.54 19 2.7 0.14
16 15 0.40 37 3.6 0.10
Mean 0.10
±SEM 0.01
A
Normal subjects
136 0.90 131 11.0 0.08
B 120 0.88 136 13.5 0.10
C 111 0.95 81 6.8 0.08
D 104 0.88 46 5.3 0.11
Mean 0.09
±SEM 0.01
The correction factor is I — (B/U), where U and B are the
observed percentages of the administered isotope that appear in
the first and second 24-hr urine samples, respectively.
SRcorr denotes corrected aldosterone secretion rate estimated
by multiplying the observed aldosterone secretion rate by a cor-
rection factor based on the rate of isotope excretion [33], ER
excretion rate of aldosterone-18-glucuronide.
whereas a significant increase occurred in the nor-
mal subjects. In subgroup B, mean recumbent
plasma aldosterone concentration was significantly
greater than that in the normal subjects.
Assessment of renin secretion. In the patients
with hypoaldosteronism, mean PRA was signifi-
cantly less than the mean in the normal subjects and
subgroup B patients (Table 2, Fig. 4). These dif-
ferences in mean values between groups were evi-
dent in both the recumbent and upright postures. In
4 of the patients with hypoaldosteronism, PRA was
within the range of values for the normal subjects in
both the recumbent and upright postures. These 4
patients have been designated as having normo-
reninemic" hypoaldosteronism (Fig. 4). None of
the remaining 19 patients with hypoaldosteronism
achieved normal levels of PRA during postural
stimulation. These patients are designated as having
"hyporeninemic" hypoaldosteronism.
The ages of II of these 19 patients with hypore-
ninemic hypoaldosteronism fell within the range
of ages of the normal subjects. Within this age range
(40 to 62 years), there was no overlap in the upright
values of PRA compared to normal subjects (N = 9)
and patients from subgroup B (N = 6). No correla-
tion between PRA and age was observed in either
subgroup A or B patients. In the normal subjects, a
significant negative correlation was observed be-
tween supine but not upright PRA and age (supine
PRA, —0.03. age + 2.l;r = —0.53;P <0.05).
Effect of renin on aldosterone production. In the
patients with hyporeninemic hypoaldosteronism,
mean PRA increased significantly when the dietary
intake of sodium was restricted, but the magnitude
of the increase was significantly less than that in the
normal subjects similarly studied (Table 4). Urinary
excretion and plasma concentration of aldosterone
also increased significantly but subnormally in re-
sponse to salt restriction. Over the range of increas-
es in PRA achieved in these studies by changes both
in salt intake and posture, mean plasma aldosterone
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Fig. 3. A Relationship between urinary aldosterone excretion
and a/dos terone secretion rate in seven patients vith chronic
renal insufficiency (solid circles) and four normalsubjects (open
circles). Values for aldosterone secretion rate were corrected for
the delay in isotope excretion that occurs in patients with im-
paired renal function (Table 3). A highly significant positive lin-
ear correlation was noted between these two measurements
when the patients and normal subjects were combined. The mea-
surements also correlated when the patients (y = 0.07x + 0.81;r
= O.91;P <0.005)and the normal subjects(y = 0.08x + 0.83;r =
0.96; P < 0.005) were considered individually; both slopes and
intercepts were nearly identical. B Relationship between urinary
a/dosterone excretion and mean circadian plasma aldosterone
concentration in three patients with chronic renal insufficiency
(pios. 8, 23, and 24) (solid circles) and three normal subjects
(open circles). The mean circadian plasma aldosterone concen-
tration was calculated from plasma samples obtained every 4
hours during the same 24-hour period in which the urinary al-
dosterone excretion rate was measured. A highly significant pos-
itive linear correlation was noted between these two measure-
ments.
concentration correlated with mean PRA in both
the patients with hyporeninemic hypoaldosteronism(r = 0.97, P <0.01) and the normal subjects (r =
0.98, P < 0.001): the slopes of the linear regression
lines were not significantly different in the two
groups, whereas the y-intercept was significantly
greater in the patients with hyporeninemic hypoal-
dosteronism (Fig. 5A). In the 2 patients with normo-
reninemic hypoaldosteronism in whom PRA was in-
creased further by sodium depletion, the increase in
plasma aldosterone concentration was blunted (Fig.
SB)
Effect of potassiu,n on aldosterone production.
The influence of potassium on aldosterone produc-
tion was specifically examined in the 4 patients with
normoreninemic hypoaldosteronism. In 3 of the 4
patients, serum potassium concentrations were 5.0
mEq/liter or less under control conditions. In these
patients, potassium intake was increased to in-
crease the serum potassium concentration. In these
3 potassium-loaded patients and in the fourth pa-
tient whose serum potassium intake exceeded 5.0
mEq/liter without potassium loading, the values of
plasma aldosterone concentration were compared
with those of normal subjects and patients from
subgroup B (Fig. 6). For the purposes of this com-
parison, we selected patients from subgroup B and
normal subjects who had PRA values within the
range of values for the patients with normoreninem-
ic hypoaldosteronism. The mean value of plasma a!-
dosterone concentration in the patients with normo-
reninemic hypoaldosteronism was significantly less
than that in the patients from subgroup B and was
no greater than that in the normal subjects despite
significantly greater serum potassium concentra-
tions (Fig. 6). Mean urinary aldosterone excretion
in the 4 patients with normoreninemic hypoaldoste-
ronism (4.0 1.3 p.g/24 hours) was significantly
lower than the mean in the patients from subgroup
B (8.5 0.4, P <0.02) and the normal subjects (9.2
l.6,P <0.05).
Discussion
The results of this study of 31 patients with hy-
perkalemia and moderately severe chronic renal in-
sufficiency indicate that isolated hypoaldosteronism
occurs commonly in this clinical setting. The diag-
nosis of isolated hypoaldosteronism was based on
evaluation of urinary excretion rates of aldosterone
in relation to the serum potassium concentration,
inasmuch as hyperkalemia itself ordinarily stimu-
lates aldosterone secretion [25, 26, 35—37]. Aldoste-
rone excretion rates in patients with chronic hyper-
kalemia should be compared with values obtained
in normal subjects who also have chronic hyper-
kalemia, but no such data are available. We as-
sessed aldosterone secretion in our patients by eval-
uation of the ratio of urinary aldosterone excretion
to the serum potassium concentration (UA)dOV/SK)
and thereby delineated two subgroups (Fig. I). In 23
of the 31 patients studied, UAId(,V/SK was sub-
normal, and these patients were diagnosed as hav-
ing hypoaldosteronism (subgroup A). The UAIdOV/
SK was within the range observed in normal sub-
jects in the remaining 8 patients (subgroup B).
It is possible that the urinary excretion rate of al-
dosterone-18-glucuronide is not a valid index of the
aldosterone secretion rate in patients with chronic
renal insufficiency, inasmuch as this metabolite of
aldosterone is principally of renal origin [24]. Be-
cause the ratio of the excretion of this metabolite to
the aldosterone secretion rate was not reduced in
comparison with the observed ratios in normal sub-
jects (Table 3), it seems unlikely that the subnormal
excretion rate observed in the patients with isolated
hypoaldosteronism was due to impaired renal me-
tabolism of aldosterone. Furthermore, the observa-
tion that the excretion rate of aldosterone-18-glu-
curonide correlated highly with the aldosterone se-
cretion rate and the mean circadian plasma
aldosterone concentration (Fig. 3) suggests that
measurement of this metabolite provides a reliable
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Table 4. Effects of restriction of dietary sodium intake in patients with hyporeninemic hypoaldosteronism and normal subjects
R2 0.8 1.3 1.9 U
R4 1.3 1.3 1.4 U
R6 2.2 2.6 4.4 U
R7 1.9 4.4 8.4 U
R9 2.4 3.7 5.3 U
R
10 2.4 2.6 — U
R
II 2.6 4.7 5.3 U
R
13 3.1 5.3 — U
R14 4.0 — 8.4 U
R17 4.5 6.4 8.4 U
R18 4.5 6.4 7.6 U
R19 5.0 10.4 — U
R20 5.1 — 8.3 U
R
22 6.1 11.8 14.8 U
R
Mean 3.3 5.1* 6.8*
C denotes control period, 3 is day 3 of dietary sodium restriction, 5 is day 5 of dietary sodium restriction, R is after overnight re-
cumbency, U is after four hours upright activity. Mean values differed significantly from the corresponding mean control values at
tO.00l, *0.01 and §0.05 probability level, respectively (Student's I test for paired variables).
h intergroup comparisons were carried out by Student's t test for unpaired variables.
means of assessing both the production rate and the
integrated plasma concentrations of the hormone
regardless of the presence of renal insufficiency.
Isolated hypoaldosteronism has been recognized
with increasing frequency in hyperkalemic patients
who have chronic renal insufficiency [16, 19—23]. In
our study of 31 patients who were selected only for
the presence of severe hyperkalemia in the setting
of chronic glomerular insufficiency, we found an in-
cidence of hypoaldosteronism of approximately
75% (subgroup A).
In the remaining 25% of patients who did not
have overt hypoaldosteronism (subgroup B), al-
dosterone production may have been abnormally
Patient
no.
.Urinary
C
Plasma hormones
aldosterone
excretion Aldosterone Renin activity
p.g124 hr ng/dl ng/m!/hr
3 5 Posture C 3 5 C 3 5
Serum electrolytes
Sodium
mEqiliter
Potassium
mEqiliter
C 3 5 C 3 5
Hyporeninemic hypoaldosteronism
2.7 11.4 5.8 <0.1 0.3 0.5 138 139 137 4.6 5.0 4.8
2.2 5.5 2.2 <0.1 0.6 1.5 — — — — — —
3.4 3.4 3.8 0.1 <0.1 <0.1 142 141 141 4.8 4.5 4.5
4.8 5.0 5.4 0,2 0.2 0.1 — — — — — —
5.6 11.4 6.9 0.2 0,6 1.1 134 132 129 5.4 5.3 5.7
6.2 — 10.3 0.7 — 2.2 — — — — — —
7.6 13.0 24.4 0.4 2.1 2.8 135 138 134 5.0 5.1 4.8
5.7 11.1 18.4 0.5 2.8 3.4 — — — — — —
2.7 6.2 7.0 0.3 1.0 1.3 138 135 134 5.3 5.6 5.8
3.6 7.6 12.2 0.7 1.6 2.2 — — — — — —
2.2 4.0 — <0.1 <0.1 — 138 136 — 5.3 5.8 —
2.1 1.7 — <0.1 0.1 — — — — — — —
8.0 13.4 26.9 <0.1 0.2 1.7 141 142 138 5.7 5.2 5.2
10.2 20.8 25.1 0.3 1.1 3.1 — — — — — —
6.4 9.7 — 0.3 0.4 — 140 137 — 5.2 5.4 —
9.3 11.7 — 0.4 0.4 — — — — — — —
5.0 — 14.7 0.3 — 1.5 141 — 133 5.0 — 5.0
12.2 — 18.6 0.5 — 1.7 — — — — — —
5.0 6.1 16.4 <0.1 0.1 0.2 140 134 137 5.9 5.5 5.6
12.9 25.1 28.9 <0.1 0.3 0.7 — — — — — —
3.4 17.9 21.3 0.1 0.2 0.4 144 132 134 5.4 5.0 5.!
35.4 36.5 45.4 0.2 0.6 0.7 — — — — — —
10.2 27.9 — 0.2 0.8 — 139 133 — 5.1 4.7 —
4.5 32.5 — 0.2 1.2 — — — — — — —
10.8 — 30.6 0.6 — 0.8 129 — 120 5.8 — 5.8
9.7 — 33.8 0.7 — 0.8 — — — — — —
5.8 7.8 15.7 0.4 0.2 0.8 131 129 130 5.7 5.6 5.5
9.5 20.2 33.3 0.6 0.5 0.8 — — — — — —
5.6 ll.0 l5.8t 0.2 0.5 1.0* 138 136 133* 5.3 5.2 5.2
±0.8 ±2.0 ±2.8 ±0.1 ±0.2 ±0.2 ±1 ±1 ±2 ±0.1 ±0.1 ±0.1
U 9.2±2.2
l6.2 21.2* 0.4 0.8 1.6*
±3.5 ±4.0 ±0,1 ±0.2 ±0.3
—
—
—
—
—
—
—
—
— —
— —
R 7.8±1.3
Normal subjects (N = 5)
20.1 — 0.9 2.4 —
±6.2 ±0.2 0.4
142
±1
141
±3
— 4.3
±0.2
4.4 —
±0.3
U 20.7
±4.2
57.4 — 2.2 4.4 —
±8.8 ±0.6 ±1.0
— —
R NS
Intergroup comparisons: P valuesb
NS — <0.001 <0.001 — NS <0.05 — <0.001 <0.01 —
U <0.025 <0.001 — <0.001 <0.001 — — —
Mean 8.5 28.2* —
± SEM 0.7 2.7
<0.001 <0.001
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Plasma renin activity, ng/m//hr
Fig. 4. Values for plasma renin activity (PRA) obtained after
overnight recumbency and after 4 hours of upright activity in
patients with isolated hypoaldosteronism (solid symbols), chron-
ic renal insufficiency without hypoaldosteronism (asterisks), and
normal subjects (open circles).
Fig. 5. Relationship between plasma aldosterone concentration
and plasma renin activity in patients with isolated hypoaldoste-
ronism (IH) (solid symbols) and normal subjects (open circles)
prior to and during sodium depletion. A Data plotted as the
mean SEM during a control period and after 3 to 5 days of
dietary sodium restriction for 14 patients with hyporeninemic hy-
poaldosteronism and 5 normal subjects (see Table 4). As shown
by the regression lines, a significant positive linear correlation
between these variables was observed both in the patients with
hyporeninemic hypoaldosteronism (y = 10.8x + 5.1;r = 0.97;P
<0.01) and in the normal subjects (y = 14.5x —9.4;r = 0.98;P <
0.001). They intercept was significantly greater (P <0.001) in the
patients with hyporeninemic hypoaldosteronism than it was in
the normal subjects, but the slopes did not differ significantly in
the two groups (analysis of covariance). B Individual data ob-
tained before and during sodium depletion in two patients with
normoreninemic hypoaldosteronism. Upright triangle denotes
furosemide; inverted triangle, dietary sodium restriction. The re-
gression lines from A are reproduced (dotted lines) for purposes
of comparison.
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Fig. 6. Comparison of plasma aldosterone concentration at simi-
lar levels of plasma renin activity in patients with normoreninem-
ic hypoaldosteronism, chronic renal insufficiency without hy-
poaldosteronism and normal subjects: lack of response to hyper-
kalemia in patients with normoreninemic hypoaldosteronism.
Overnight recumbent plasma aldosterone concentrations ob-
served in the four patients with normoreninemic hypoaldosteron-
ism (solid symbols) are compared with the values observed in
normal subjects (open circles) and patients with chronic renal
insufficiency without hypoaldosteronism (asterisks) who had
similar levels of PRA. The mean value in the patients with nor-
moreninemic hypoaldosteronism (8.6 2.4 ngldl) was signifi-
cantly less (P < 0.01) than that in the patients without hypoal-
dosteronism (23.3 2.8 ngldl) and was similar to that in normal
subjects (10.1 1.6 ngldl) despite significantly greater levels of
serum potassium concentration (normoreninemic hypoaldoste-
ronism vs. chronic renal insufficiency, P <0.05, vs. normal sub-
jects, P < 0.001, respectively).
low for the degree of hyperkalemia. The individual
values for the ratio UAIdOV/SK in subgroup B were
within the range of values observed in the normal
subjects, but the mean ratio was significantly less
than that in the normal subjects (Fig. 1; 1.7 [SEMI
0.1 vs. 2.5 0.2, respectively;P <0.05). A much
greater value of this ratio might have been obtained
in the normal subjects had they been hyperkalemic,
inasmuch as aldosterone production is ordinarily
sensitive to very small increases in serum potas-
sium concentration (0.2 to 0.3 mEq/liter) [26]. The
1 2
Plasma renin activity, ng/m//hr
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possibility that patients in subgroup B have a rela-
tive state of hypoaldosteronism is further suggested
by the finding that normokalemic patients with
chronic renal insufficiency characteristically have
substantially higher plasma aldosterone concentra-
tions than do patients in subgroup B [38].
The results of this study also suggest that the oc-
currence of aldosterone deficiency may contribute
to the pathogenesis of hyperkalemia in patients with
chronic renal insufficiency. In both subgroups of pa-
tients, a significant positive correlation was ob-
served between the serum potassium concentration
and the steady-state urinary excretion rate of potas-
sium (Fig. 7). Urinary potassium excretion in the
steady state is presumed to reflect net dietary load
of potassium (diet minus stool potassium). A signifi-
cantly greater degree of hyperkalemia was observed
in the patients with hypoaldosteronism (subgroup
A) than in those without overt hypoaldosteronism
(subgroup B) in relation to the net dietary load of
potassium (Fig. 7). It is conceivable that the pres-
ence of hyperkalemia in subgroup B, albeit of lesser
severity than in subgroup A, is related to the rela-
tive degree of hypoaldosteronism in these patients.
Viewed in another way, these data indicate that ren-
al clearance of potassium is impaired in hyper-
kalemic patients with chronic renal insufficiency,
and the magnitude of this impairment is related to
the extent to which aldosterone secretion is sub-
normal.
The occurrence of hypoaldosteronism in patients
in subgroup A was associated with hyporeninemia
in 83% of the cases. Plasma renin activity was sub-
normal in 19 patients and normal in 4 patients, and
these 2 groups have been designated as having
hyporeninemic and normoreninemic hypoaldoste-
ronism, respectively. The findings in the patients
with hyporeninemic hypoaldosteronism suggest
that the occurrence of hyporeninemia accounts for
the hypoaldosteronism. In response to the stimula-
tion of renin secretion by restriction of sodium in-
80 take and upright posture, plasma aldosterone con-
centration increased normally as PRA increased, as
predicted from the observed relationship between
these variables in the normal subjects studied:
plasma aldosterone concentration was a positive
linear function of PRA in both groups and the slopes
in the two groups were not significantly different
(Fig 5A). At any level of PRA, plasma aldosterone
concentration was not subnormal in the patients,
suggesting that if PRA had been normal, plasma al-
dosterone concentration would not have been re-
duced. Accordingly, the adrenal response to stimu-
lation by the renin-angiotensin system appears to be
unimpaired in patients with hyporeninemic hypoal-
dosteronism, and the magnitude of the reduction in
PRA appears to be quantitatively sufficient to ac-
count for the hypoaldosteronism.
The degree of hypoaldosteronism in the patients
with hyporeninemia was not even as severe as
would have been predicted from the degree of re-
duction of PRA. Plasma aldosterone concentration
for any given PRA was significantly greater than in
normal subjects: they-intercept of the linear regres-
sion equation was significantly greater (P < 0.001)
in the patients with hyporeninemic hypoaldosteron-
ism than it was in the normal subjects (Fig. 5A).
This difference suggests that an aldosterone stimu-
latory factor other than renin in the patients with
hyporeninemic hypoaldosteronism was present that
was not present in the normal subjects. This factor
may have been hyperkalemia, because serum potas-
sium concentration was significantly greater than
normal values (Table 2), and the patients with the
highest serum potassium concentrations had the
greatest excretion rates of aldosterone (Fig. 2). The
slope of the relationship between urinary aldoste-
rone excretion and serum potassium concentration
was not significantly different from that for the pa-
tients with chronic renal insufficiency without hy-
poaldosteronism, which suggests that the aldoste-
rone secretory response to potassium was not im-
paired. These findings thus indicate that in patients
L
8
C0
C
a,C,c00
E
00.
E
U,Ci
5.5 -
4.5 -
:•
. SS.
.
*
*
Fig. 7. Relationship between serum potassium concentration and
urinary potassium excretion in patients ii'ith isolated hypoal—
dosteronism (subgroup A) (solid symbols) and patients with
c/Ironic renal insufficiency without hvpoaldosteronisrn (subgroup
B) (asterisks). As indicated by the regression lines, a significant
positive correlation between these variables was observed both
in the patients in subgroup A (y = 0.020x + 4.72: r = 0.56; P <
0.01) and in those in subgroup B (',' = 0.013x + 4.38; r = 0.83; P
< 0.01). They intercept was significantly greater (P < 0.001) in
the patients in subgroup A than it was in those in subgroup B, but
the slopes did not differ significantly in the two groups (analysis
of covariance).
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with hyporeninemic hypoaldosteronism the reduc-
tion in aldosterone production caused by renin defi-
ciency is limited, at least in part, by the occurrence
of hyperkalemia and that the aldosterone secretory
mechanism is normally responsive to potassium.
The role of hyperkalemia in the maintenance of
aldosterone secretion in patients with hyporeninem-
ic hypoaldosteronism may be most readily appreci-
ated when the plasma aldosterone levels after over-
night recumbency in these patients are compared
with those of normal subjects. Under these condi-
tions, the effect of hyporeninemia to reduce aldoste-
rone secretion would be expected to be minimal, in-
asmuch as renin secretion is minimal owing to lack
of postural stimulation. Other factors capable of
stimulating aldosterone secretion, such as hyper-
kalemia, may be sufficient to restore aldosterone to
normal or nearly normal levels (Tables 2 and 4).
When comparable degrees of hyperkalemia are
present in patients in whom renin levels are not re-
duced (subgroup B), it is not surprising that plasma
aldosterone levels are greater than normal.
The reduction of aldosterone production caused
by renin deficiency may have been limited further
by the occurrence of acidosis and hyponatremia,
which might also stimulate aldosterone secretion
[37, 39—41]. In comparison with normal subjects,
the patients with hypoaldosteronism had signifi-
cantly reduced control levels of serum total carbon
dioxide and sodium (Table 1) and further significant
reduction in serum sodium concentration during so-
dium restriction (Table 4). A quantitative relation-
ship between the degree of acidosis and/or hypona-
tremia and aldosterone production has not been es-
tablished in normal subjects, and therefore it is not
known to what extent these factors contributed to
the maintenance of aldosterone production in hypo-
reninemic patients.
The results of this study permit no conclusion
concerning the pathogenesis of hyporeninemia in
patients with chronic renal insufficiency. It has been
postulated that the reduction in renin secretion is a
consequence of a primary renal pathologic process
[15, 16, 19]. Six of our 19 patients with hyporenin-
emia had diabetes mellitus. In patients with hypo-
reninemic hypoaldosteronism who have diabetes
mellitus, distinct morphologic abnormalities in the
renin-secreting juxtaglomerular apparatus have
been described [42]. The frequent occurrence of
juxtaglomerular pathology in patients with diabetic
nephropathy [43] may account for the observation
that the renin secretory capacity is frequently re-
duced in such patients [44]. Systematic studies of
renal histopathology in nondiabetic patients with
hyporeninemic hypoaldosteronism have not been
reported. In our patients who had chronic renal dis-
ease of diverse causes, there was no correlation be-
tween the degree of renal insufficiency, as reflected
by the clearance of creatinine, and the degree of re-
nm deficiency (Table I). Additional mechanisms
that have been suggested to account for the hypo-
reninemia in patients with hypoaldosteronism in-
clude (a) chronic physiologic suppression of renin
secretion by extracellular fluid volume expansion
due to impaired renal clearance of sodium {2l],(b) a
functional abnormality of the juxtaglomerular appa-
ratus characterized by the secretion of an inactive
form of renin (so-called big" renin) [22], and (c)
chronic lack of stimulation of renin secretion by the
sympathetic nervous system due to autonomic neu-
ropathy [45]. The observation that hypoaldosteron-
ism, as reflected by plasma aldosterone concentra-
tion, is more readily apparent when samples obtained
after postural stimulation in these patients are
compared with those of normal subjects (Table 2) is
consistent with a dysfunction of the autonomic ner-
vous system in controlling renin release [45, 46].
An additional factor that must be considered in
examining the pathogenesis of the impaired renin
and aldosterone secretion in patients with hypore-
ninemic hypoaldosteronism is the age of the patient
population. As in our study, the average age of pa-
tients reported with this syndrome has been be-
tween 50 and 70 years [5-23]. Both aldosterone se-
cretion [47] and plasma aldosterone concentration
[48] have been reported to decrease normally with
age, a finding that may reflect in part a normal de-
cline in PRA with age [48]. In our study, we found
that the ratio UAIdOV/SK correlated negatively with
age in subgroup A, but because this ratio was still
significantly lower in the patients with hypoaldoste-
ronism than it was in normal subjects and patients
from subgroup B of comparable age, other factors
besides age must be involved.
In four patients, the occurrence of hypoaldoste-
ronism could not be attributed to hyporeninemia,
because their PRA levels were normal (Fig. 4).
When the PRA levels were increased further by so-
dium depletion in two of these patients, hypoal-
dosteronism persisted (Fig. SB). In all four patients,
an impaired aldosterone secretory response to hy-
perkalemia was also present (Fig. 6). The possibility
can be considered that hypoaldosteronism in these
patients results from a primary adrenal dysfunction.
Evidence for a primary disturbance in the biosyn-
thetic pathway of aid osterone in adult patients with
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isolated hypoaldosteronism has been reported:
measurements of biosynthetic precursors of aldo-
sterone have been interpreted as indicating a defect
in corticosterone methyl oxidase [11, 15, 22]. The
results of these reported studies, however, do not
conclusively establish that hypoaldosteronism was
due solely to a primary adrenal dysfunction in-
asmuch as a compensatory state of hypereninemia
was not present, as it is in patients with Addison's
disease [16] and infants with inherited defects in a!-
dosterone biosynthesis [4]. Conceivably, primary
impairments in reni and aldosterone secretion can
coexist [22], and the deficiency of renin may con-
tribute to the pathogenesis of the hypoaldosteron-
ism.
Summary. Our findings indicate that hypoaldo-
steronism occurs commonly (23/31 patients) in hy-
perkalemic patients with chronic renal insufficiency
and that the deficiency of aldosterone contributes to
the pathogenesis of the hyperkalemia. In most pa-
tients (83%), hypoaldosteronism could be account-
ed for by deficient renal secretion of renin, but in
some patients (17%) overt renin deficiency did not
appear to be present, and therefore other (uniden-
tified) causes of aldosterone deficiency must be in-
voked. The results also indicate that the urinary ex-
cretion rate of aldosterone-l8-glucuronide provides
a valid index of aldosterone secretion rate in this
group of patients.
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